{"id":101,"date":"2019-09-22T17:51:56","date_gmt":"2019-09-22T21:51:56","guid":{"rendered":"https:\/\/opentextbc.ca\/nursingpharmacology\/chapter\/3-8-monobactams\/"},"modified":"2023-03-07T12:39:12","modified_gmt":"2023-03-07T17:39:12","slug":"3-8-monobactams","status":"publish","type":"chapter","link":"https:\/\/opentextbc.ca\/nursingpharmacology\/chapter\/3-8-monobactams\/","title":{"raw":"3.9 Monobactams","rendered":"3.9 Monobactams"},"content":{"raw":"Like penicillins, cephalosporins, and carbapenems, monobactams also have a beta-lactam ring structure.\r\n\r\n<strong>Indications for Use:<\/strong> Monobactams are narrow-spectrum antibacterial medications that are used primarily to treat gram-negative bacteria such as Pseudomonas aeruginosa.\r\n\r\n<strong>Mechanism of Action:<\/strong> Monobactams are bactericidal and work to inhibit bacterial cell wall synthesis.\r\n\r\n<strong>Nursing Considerations Across the Lifespan:\u00a0<\/strong> Monobactams are considered safe for use in pediatrics. Some dose adjustments are required based on renal dysfunction in older adults. Monobactams can be given during pregnancy if the client is allergic to other, more preferred, antibiotics.\r\n\r\n<strong>Specific Administration Considerations:<\/strong> Clients taking monobactams may experience adverse effects similar to other beta-lactam medications, so nurses should monitor for GI symptoms, skin sensitivities, and coagulation abnormalities.\r\n\r\n<strong>Client Teaching &amp; Education: <\/strong>Clients should monitor for signs of superinfection and report any occurrence to the provider. If the client experiences fever and bloody diarrhea, they should contact the provider immediately.\u00a0 The client should also be advised to notify the provider immediately if symptoms progress or if any sign of allergic response occurs.[footnote]uCentral from Unbound Medicine. <a href=\"https:\/\/www.unboundmedicine.com\/ucentral\" rel=\"noopener noreferrer\">https:\/\/www.unboundmedicine.com\/ucentral<\/a>[\/footnote]<strong>\u00a0<\/strong>\r\n<h1>Monobactams Medication Card<\/h1>\r\nNow let's take a closer look at the medication card for Monobactams.[footnote]Daily Med, <a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/index.cfm\" rel=\"noopener noreferrer\">https:\/\/dailymed.nlm.nih.gov\/dailymed\/index.cfm<\/a>, used for hyperlinked medications in this module. Retrieved June 27, 2019.[\/footnote][footnote]UpToDate (2021). <em>Aztreonam<\/em>. <a href=\"https:\/\/www.uptodate.com\/contents\/search\">https:\/\/www.uptodate.com\/contents\/search<\/a>[\/footnote] Because information about medication is constantly changing, nurses should always consult evidence-based resources to review current recommendations before administering specific medication.\r\n<div class=\"textbox textbox--learning-objectives\"><header class=\"textbox__header\">\r\n<h2 class=\"textbox__title\">Medication Card 3.9.1: Monobactams (Azteronam)<\/h2>\r\n<\/header>\r\n<div class=\"textbox__content\">\r\n\r\n<strong>Class:<\/strong> Monobactams\r\n\r\n<strong>Prototypes:<\/strong> azteronam\r\n\r\n<strong>Mechanism:\u00a0 <\/strong>Bactericidal. Narrow-spectrum.\r\n<h3>Therapeutic Effects<\/h3>\r\n<ul>\r\n \t<li>Monitor for systemic signs of infection:\r\n<ul>\r\n \t<li>WBC<\/li>\r\n \t<li>Temperature<\/li>\r\n \t<li>Culture results<\/li>\r\n<\/ul>\r\n<\/li>\r\n \t<li>Monitor site of infection for improvement<\/li>\r\n<\/ul>\r\n<h3>Administration<\/h3>\r\n<ul>\r\n \t<li>Can be administered IM, IV, or via inhalation<\/li>\r\n \t<li>Peak: 60 minutes via IM<\/li>\r\n \t<li>\u00bd life:\u00a0 1.5-2 hours with normal renal function<\/li>\r\n<\/ul>\r\n<h3>Indications<\/h3>\r\n<ul>\r\n \t<li>used primarily to treat gram-negative bacteria such as Pseudomonas aeruginosa.<\/li>\r\n \t<li>Meropenem: only drug for bacterial meningitis<\/li>\r\n<\/ul>\r\n<h3>Contraindications<\/h3>\r\n<ul>\r\n \t<li>Check for allergies to any beta lactams \u2013 penicillin, cephalosporins, or carbapenems<\/li>\r\n \t<li>Impaired renal function<\/li>\r\n<\/ul>\r\n<h3>Side Effects<\/h3>\r\n<ul>\r\n \t<li>hematologic neutropenia<\/li>\r\n \t<li>increased serum liver enzymes<\/li>\r\n \t<li>GI: GI upset, <strong>N\/V, diarrhea, dehydration, <\/strong>electrolyte imbalance<\/li>\r\n \t<li>Skin sensitivities<\/li>\r\n \t<li>Coagulation abnormalities<\/li>\r\n \t<li>Superinfection<\/li>\r\n<\/ul>\r\n<h3>Nursing Considerations<\/h3>\r\n<ul>\r\n \t<li>Monitor renal and liver function<\/li>\r\n \t<li>Monitor for signs of anaphylaxis during first dose<\/li>\r\n \t<li>Monitor skin<\/li>\r\n \t<li>Monitor bowels<\/li>\r\n \t<li>Monitor labs<\/li>\r\n<\/ul>\r\n<\/div>\r\n<\/div>\r\n<div class=\"textbox textbox--key-takeaways\"><header class=\"textbox__header\">\r\n<p class=\"textbox__title\">Clinical Reasoning and Decision-Making Activity 3.8a<\/p>\r\n\r\n<\/header>\r\n<div class=\"textbox__content\">\r\n\r\n<strong>Using the above information, consider the following clinical scenario question:<\/strong>\r\n\r\nA client with cystic fibrosis is diagnosed with ventilator-associated pneumonia and is prescribed Aztreonam 1 gm IV daily for a suspected Pseudomonas aeruginosa infection. The nurse reviews the culture results that just arrived and notices that the results indicate the infection is caused by Methicillin-resistant Staphylococcus aureus. Will this medication be effective against this bacteria? What is the nurse's next best response?\r\n\r\nNote: Answers to the activities can be found in the \"<a href=\"https:\/\/opentextbc.ca\/nursingpharmacology\/chapter\/chapter-3\/\">Answer Key<\/a>\" sections at the end of the book.\r\n\r\n<\/div>\r\n<\/div>","rendered":"<p>Like penicillins, cephalosporins, and carbapenems, monobactams also have a beta-lactam ring structure.<\/p>\n<p><strong>Indications for Use:<\/strong> Monobactams are narrow-spectrum antibacterial medications that are used primarily to treat gram-negative bacteria such as Pseudomonas aeruginosa.<\/p>\n<p><strong>Mechanism of Action:<\/strong> Monobactams are bactericidal and work to inhibit bacterial cell wall synthesis.<\/p>\n<p><strong>Nursing Considerations Across the Lifespan:\u00a0<\/strong> Monobactams are considered safe for use in pediatrics. Some dose adjustments are required based on renal dysfunction in older adults. Monobactams can be given during pregnancy if the client is allergic to other, more preferred, antibiotics.<\/p>\n<p><strong>Specific Administration Considerations:<\/strong> Clients taking monobactams may experience adverse effects similar to other beta-lactam medications, so nurses should monitor for GI symptoms, skin sensitivities, and coagulation abnormalities.<\/p>\n<p><strong>Client Teaching &amp; Education: <\/strong>Clients should monitor for signs of superinfection and report any occurrence to the provider. If the client experiences fever and bloody diarrhea, they should contact the provider immediately.\u00a0 The client should also be advised to notify the provider immediately if symptoms progress or if any sign of allergic response occurs.<a class=\"footnote\" title=\"uCentral from Unbound Medicine. https:\/\/www.unboundmedicine.com\/ucentral\" id=\"return-footnote-101-1\" href=\"#footnote-101-1\" aria-label=\"Footnote 1\"><sup class=\"footnote\">[1]<\/sup><\/a><strong>\u00a0<\/strong><\/p>\n<h1>Monobactams Medication Card<\/h1>\n<p>Now let&#8217;s take a closer look at the medication card for Monobactams.<a class=\"footnote\" title=\"Daily Med, https:\/\/dailymed.nlm.nih.gov\/dailymed\/index.cfm, used for hyperlinked medications in this module. Retrieved June 27, 2019.\" id=\"return-footnote-101-2\" href=\"#footnote-101-2\" aria-label=\"Footnote 2\"><sup class=\"footnote\">[2]<\/sup><\/a><a class=\"footnote\" title=\"UpToDate (2021). Aztreonam. https:\/\/www.uptodate.com\/contents\/search\" id=\"return-footnote-101-3\" href=\"#footnote-101-3\" aria-label=\"Footnote 3\"><sup class=\"footnote\">[3]<\/sup><\/a> Because information about medication is constantly changing, nurses should always consult evidence-based resources to review current recommendations before administering specific medication.<\/p>\n<div class=\"textbox textbox--learning-objectives\">\n<header class=\"textbox__header\">\n<h2 class=\"textbox__title\">Medication Card 3.9.1: Monobactams (Azteronam)<\/h2>\n<\/header>\n<div class=\"textbox__content\">\n<p><strong>Class:<\/strong> Monobactams<\/p>\n<p><strong>Prototypes:<\/strong> azteronam<\/p>\n<p><strong>Mechanism:\u00a0 <\/strong>Bactericidal. Narrow-spectrum.<\/p>\n<h3>Therapeutic Effects<\/h3>\n<ul>\n<li>Monitor for systemic signs of infection:\n<ul>\n<li>WBC<\/li>\n<li>Temperature<\/li>\n<li>Culture results<\/li>\n<\/ul>\n<\/li>\n<li>Monitor site of infection for improvement<\/li>\n<\/ul>\n<h3>Administration<\/h3>\n<ul>\n<li>Can be administered IM, IV, or via inhalation<\/li>\n<li>Peak: 60 minutes via IM<\/li>\n<li>\u00bd life:\u00a0 1.5-2 hours with normal renal function<\/li>\n<\/ul>\n<h3>Indications<\/h3>\n<ul>\n<li>used primarily to treat gram-negative bacteria such as Pseudomonas aeruginosa.<\/li>\n<li>Meropenem: only drug for bacterial meningitis<\/li>\n<\/ul>\n<h3>Contraindications<\/h3>\n<ul>\n<li>Check for allergies to any beta lactams \u2013 penicillin, cephalosporins, or carbapenems<\/li>\n<li>Impaired renal function<\/li>\n<\/ul>\n<h3>Side Effects<\/h3>\n<ul>\n<li>hematologic neutropenia<\/li>\n<li>increased serum liver enzymes<\/li>\n<li>GI: GI upset, <strong>N\/V, diarrhea, dehydration, <\/strong>electrolyte imbalance<\/li>\n<li>Skin sensitivities<\/li>\n<li>Coagulation abnormalities<\/li>\n<li>Superinfection<\/li>\n<\/ul>\n<h3>Nursing Considerations<\/h3>\n<ul>\n<li>Monitor renal and liver function<\/li>\n<li>Monitor for signs of anaphylaxis during first dose<\/li>\n<li>Monitor skin<\/li>\n<li>Monitor bowels<\/li>\n<li>Monitor labs<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<div class=\"textbox textbox--key-takeaways\">\n<header class=\"textbox__header\">\n<p class=\"textbox__title\">Clinical Reasoning and Decision-Making Activity 3.8a<\/p>\n<\/header>\n<div class=\"textbox__content\">\n<p><strong>Using the above information, consider the following clinical scenario question:<\/strong><\/p>\n<p>A client with cystic fibrosis is diagnosed with ventilator-associated pneumonia and is prescribed Aztreonam 1 gm IV daily for a suspected Pseudomonas aeruginosa infection. The nurse reviews the culture results that just arrived and notices that the results indicate the infection is caused by Methicillin-resistant Staphylococcus aureus. Will this medication be effective against this bacteria? What is the nurse&#8217;s next best response?<\/p>\n<p>Note: Answers to the activities can be found in the &#8220;<a href=\"https:\/\/opentextbc.ca\/nursingpharmacology\/chapter\/chapter-3\/\">Answer Key<\/a>&#8221; sections at the end of the book.<\/p>\n<\/div>\n<\/div>\n<hr class=\"before-footnotes clear\" \/><div class=\"footnotes\"><ol><li id=\"footnote-101-1\">uCentral from Unbound Medicine. <a href=\"https:\/\/www.unboundmedicine.com\/ucentral\" rel=\"noopener noreferrer\">https:\/\/www.unboundmedicine.com\/ucentral<\/a> <a href=\"#return-footnote-101-1\" class=\"return-footnote\" aria-label=\"Return to footnote 1\">&crarr;<\/a><\/li><li id=\"footnote-101-2\">Daily Med, <a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/index.cfm\" rel=\"noopener noreferrer\">https:\/\/dailymed.nlm.nih.gov\/dailymed\/index.cfm<\/a>, used for hyperlinked medications in this module. Retrieved June 27, 2019. <a href=\"#return-footnote-101-2\" class=\"return-footnote\" aria-label=\"Return to footnote 2\">&crarr;<\/a><\/li><li id=\"footnote-101-3\">UpToDate (2021). <em>Aztreonam<\/em>. <a href=\"https:\/\/www.uptodate.com\/contents\/search\">https:\/\/www.uptodate.com\/contents\/search<\/a> <a href=\"#return-footnote-101-3\" class=\"return-footnote\" aria-label=\"Return to footnote 3\">&crarr;<\/a><\/li><\/ol><\/div>","protected":false},"author":90,"menu_order":9,"template":"","meta":{"pb_show_title":"on","pb_short_title":"","pb_subtitle":"","pb_authors":[],"pb_section_license":""},"chapter-type":[50],"contributor":[],"license":[],"class_list":["post-101","chapter","type-chapter","status-publish","hentry","chapter-type-numberless"],"part":70,"_links":{"self":[{"href":"https:\/\/opentextbc.ca\/nursingpharmacology\/wp-json\/pressbooks\/v2\/chapters\/101","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/opentextbc.ca\/nursingpharmacology\/wp-json\/pressbooks\/v2\/chapters"}],"about":[{"href":"https:\/\/opentextbc.ca\/nursingpharmacology\/wp-json\/wp\/v2\/types\/chapter"}],"author":[{"embeddable":true,"href":"https:\/\/opentextbc.ca\/nursingpharmacology\/wp-json\/wp\/v2\/users\/90"}],"version-history":[{"count":6,"href":"https:\/\/opentextbc.ca\/nursingpharmacology\/wp-json\/pressbooks\/v2\/chapters\/101\/revisions"}],"predecessor-version":[{"id":1632,"href":"https:\/\/opentextbc.ca\/nursingpharmacology\/wp-json\/pressbooks\/v2\/chapters\/101\/revisions\/1632"}],"part":[{"href":"https:\/\/opentextbc.ca\/nursingpharmacology\/wp-json\/pressbooks\/v2\/parts\/70"}],"metadata":[{"href":"https:\/\/opentextbc.ca\/nursingpharmacology\/wp-json\/pressbooks\/v2\/chapters\/101\/metadata\/"}],"wp:attachment":[{"href":"https:\/\/opentextbc.ca\/nursingpharmacology\/wp-json\/wp\/v2\/media?parent=101"}],"wp:term":[{"taxonomy":"chapter-type","embeddable":true,"href":"https:\/\/opentextbc.ca\/nursingpharmacology\/wp-json\/pressbooks\/v2\/chapter-type?post=101"},{"taxonomy":"contributor","embeddable":true,"href":"https:\/\/opentextbc.ca\/nursingpharmacology\/wp-json\/wp\/v2\/contributor?post=101"},{"taxonomy":"license","embeddable":true,"href":"https:\/\/opentextbc.ca\/nursingpharmacology\/wp-json\/wp\/v2\/license?post=101"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}